MiP Pharma Sells Homburg/Saar Facility to Famar Group
Deal News | May 20, 2025 | capiton AG
MiP Pharma, a company in the portfolio of the private equity firm capiton AG, has announced the sale of its production site located in Homburg/Saar to the Famar Group. The Famar Group is recognized as a global pharmaceutical Contract Development and Manufacturing Organization (CDMO). This strategic move will allow the Famar Group to incorporate the facility into its existing global production matrix, with plans to further develop it. The sale represents a significant step in MiP Pharma's strategic vision to focus its operations. This development is indicative of the ongoing trend of consolidation in the pharmaceutical CDMO sector, where companies seek to optimize operations and expand global footprints through strategic acquisitions.
Sectors
- Pharmaceutical Industry
- Private Equity
Geography
- Germany – The production site involved in the transaction is located in Homburg/Saar, Germany.
- Global – Famar Group operates globally and will integrate the acquired site into its worldwide network.
Industry
- Pharmaceutical Industry – The article discusses the divestment of a pharmaceutical production site, involving participants classified within the pharmaceutical sector.
- Private Equity – capiton AG, a private equity firm, is involved in the transaction, indicating the role of private equity in facilitating strategic divestments.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| MiP Pharma | Target | Company | A pharmaceutical company that sold its production site to Famar Group. |
| Famar Group | Buyer | Company | A globally operating pharmaceutical CDMO acquiring MiP Pharma's production site. |
| capiton AG | Seller | Company | Private equity firm owning MiP Pharma and overseeing the divestment. |